Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pegasys Market Position Secure, Roche Says; Dismisses PEG-Intron Data

Executive Summary

Roche expects to have firmly established its leadership position in the hepatitis C market with Pegasys by the time Schering-Plough publishes the results from its ongoing head-to-head study versus PEG-Intron

You may also be interested in...



Pegasys Gets HIV Co-Infection Claim; Market Expansion Moves Forward

Roche is looking to a new chronic hepatitis C indication for Pegasys in patients co-infected with HIV to expand its hepatitis market penetration

Pegasys Gets HIV Co-Infection Claim; Market Expansion Moves Forward

Roche is looking to a new chronic hepatitis C indication for Pegasys in patients co-infected with HIV to expand its hepatitis market penetration

Roche, Schering Look To Grow Hepatitis Market; Pegasys Share Surges

Roche and Schering-Plough are attempting to drive sales of their hepatitis products by growing the market while increasing share

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel